Human Papillomavirus Infection Clinical Trial
Official title:
A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers
This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | October 31, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Men and women aged between 18 and 35 years (inclusive) at the time of Screening Visit. - In good general health, with no significant medical history, and have no clinically significant abnormalities on vital signs, physical examination, laboratory tests, and ECG at Screening Visit and before the first vaccination of IP at the discretion of the Investigator(s) or designee. - Body Mass Index (BMI) of = 18.0 and = 32.0 (BMI will be calculated by weight in kilograms [kg]/square of height in meters [m2]) and weigh at least 50 kg at Screening Visit. - Able and willing to comply with all study requirements and study procedures. - Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures. - Male and female of childbearing age should agree to take effective contraception measures Exclusion Criteria: - Physical or psychological medical histories (within 3 months prior to Screening Visit) or ongoing conditions of any clinically significant hepatic (eg, active liver disease, hepatic impairment), renal/genitourinary (eg, renal impairment), gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, hematological disease, and/or any other medical conditions which, at the discretion of the Investigator(s), may jeopardize the safety of the participants and/or effect the results of the study. - Histories or on-going conditions of immune function impaired, congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases. - Histories or on-going conditions of malignancy, except for non-melanoma skin cancer, excised more than 2 years ago. - History of abnormal cervical biopsy results (showing cervical intraepithelial neoplasia or worse) or cervical disease (ie, surgical treatment for cervical lesions) within 5 years prior to Screening Visit. - History of a positive test for HPV infection. - Histories of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents. - Loss of spleen or functional spleen, and/or removal of spleen caused by any situation - Body temperature before vaccination = 38? for ear or temporal artery temperature or = 37.2 ? for armpit temperature before vaccination. - Systolic blood pressure = 140 mmHg and/or a diastolic blood pressure = 90 mmHg before vaccination. - Receipt of systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to Screening Visit (for corticosteroids = 20 mg/day of prednisone equivalent). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. - Receipt of immunoglobulins and/or any blood products within the 3 months prior to the first vaccination or planned administration during the study period. - Receipt of any HPV vaccination within 3 months prior to the first vaccination. Receipt of any vaccination other than HPV vaccination within 30 days prior to first vaccination. Plan to receive any vaccination within 7 days prior to the secondary or third IP vaccination. Plan to receive any vaccination within 30 days after the first, secondary, or third IP vaccination. - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first vaccination of IP. - Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills [OCPs], long-acting implantable hormones, injectable hormones, a vaginal ring, or an IUD), over the counter (OTC) medication, or herbal remedies 2 weeks prior to dosing and during course of study, unless the medication will not affect the safety and efficacy evaluations in the study at the discretion of the Investigator(s). - Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine). - Positive toxicology panel (urine test including qualitative identification of barbiturates, THC, amphetamines, benzodiazepines, opiates, and cocaine). - Positive results of hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV antibody, HPV, SARS-CoV-2, and pregnancy test. - Pregnancy or breast feeding or plan to get pregnant or breastfeed during the study. - Anything that the Investigator(s) considers that may jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data. |
Country | Name | City | State |
---|---|---|---|
Australia | Paratus Clinical Research Canberra | Canberra |
Lead Sponsor | Collaborator |
---|---|
Wuhan BravoVax Co., Ltd. | Novotech (Australia) Pty Limited, Shanghai BravoBio Co., Ltd. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety in terms of solicited adverse events | Occurrence of solicited AEs of each subject | within 7 days after each vaccination | |
Primary | Safety in terms of solicited systemic AEs | Occurrence of solicited systemic AEs of each subject | within 7 days after the first vaccination | |
Primary | Safety in terms of dose-limiting toxicity (DLT) | Percentage of participants with dose-limiting toxicity | within 30 days after the first vaccination | |
Primary | Safety in terms of unsolicited AEs | Percentage of participants with unsolicited AEs | 365 days after the first vaccination | |
Primary | Safety in terms of all solicited and unsolicited AEs | Frequency and severity of solicited and unsolicited AEs | 365 days after the first vaccination | |
Secondary | Immunogencity in terms of GMT by ELISA | GMT of anti-L2 immunoglobulin G (IgG) antibody responses | Days 1, 31, 61, 91, 121, 181, 211, and 365 | |
Secondary | Immunogencity in terms of Nab | GMT of anti-HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73 type specific serum neutralizing antibody (NAb) response | Days 1, 31, 61, 91, 121, 181, 211, and 365 | |
Secondary | Immunogencity in terms of Seroconversion rate | Seroconversion rate of anti-L2 IgG antibody and anti-HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73 type-specific serum Nab | Days 1, 31, 61, 91, 121, 181, 211, and 365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
Completed |
NCT01932697 -
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT03265743 -
HPV Vaccination in Women With Cystic Fibrosis
|
N/A | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A | |
Completed |
NCT06199128 -
Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
|
||
Active, not recruiting |
NCT01824537 -
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
|
Phase 4 | |
Completed |
NCT01265212 -
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
|
N/A | |
Unknown status |
NCT01087164 -
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
|
N/A | |
Terminated |
NCT01082861 -
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
|
Phase 4 | |
Completed |
NCT00572832 -
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT05680454 -
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
|
Phase 1 | |
Completed |
NCT04133610 -
HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs
|
N/A | |
Completed |
NCT00988884 -
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
|
Phase 3 | |
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
Completed |
NCT01694875 -
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
|
N/A | |
Completed |
NCT01205412 -
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
|
N/A |